Loading cancer entity…
Loading cancer entity…
Clinical trials
8,120 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,290)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04796922 | To Evaluate Efficacy and Safety of Parsaclisib Plus Either Rituximab or Obinutuzumab in R/R Follicular Lymphoma (FL) and Marginal Zone Lymphoma (MZL) (CITADEL-302) | withdrawn | Phase 3 | 0 | Incyte CorporationINDUSTRY | 0 | Jul 18, 2022 | clinicaltrials |
| NCT02063685 | Study to Evaluate the Efficacy of Response-adapted Strategy in Follicular Lymphoma | completed | Phase 3 | 807 | Fondazione Italiana Linfomi - ETSOTHER | 1 | Jun 21, 2022 | clinicaltrials |
| NCT01239797 | Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma(ELOQUENT - 2) | completed | Phase 3 | 646 | Bristol-Myers SquibbINDUSTRY | 23 | Jun 1, 2022 | clinicaltrials |
| NCT03029234 | Carfilzomib in Combination With Dexamethasone (Kd) in Chinese Patients With Relapsed & Refractory Multiple Myeloma | completed | Phase 3 | 126 | AmgenINDUSTRY | 1 | May 25, 2022 | clinicaltrials |
| NCT02197221 | Bortezomib-Melphalan Conditioning Regimen vs Melphalan for Frontline Transplant Eligible Patients With Multiple Myeloma(IFM2014-02) | completed | Phase 3 | 300 | University Hospital, ToulouseOTHER | 2 | May 23, 2022 | clinicaltrials |
| NCT02787239 | Clinical Study to Compare the Efficacy and Safety of Rituximab Biosimilar HLX01 and Rituximab in Combination With CHOP, in Previously Untreated Subjects With CD20+ DLBCL | completed | Phase 3 | 407 | Shanghai Henlius BiotechINDUSTRY | 1 | May 9, 2022 | clinicaltrials |
| NCT04849715 | A Study of Parsaclisib, a PI3Kδ Inhibitor, in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma(CITADEL-310) | withdrawn | Phase 3 | 0 | Incyte CorporationINDUSTRY | 0 | Apr 29, 2022 | clinicaltrials |
| NCT05334238 | Orelabrutinib Maintenance Therapy After ASCT in Primary Central Nervous System Lymphoma | unknown | Phase 3 | 174 | Ruijin HospitalOTHER | 1 | Apr 19, 2022 | clinicaltrials |
| NCT02566395 | Stem Cell Transplantation From HLA Partially-Matched Related Donors for Patients With Hematologic Malignancies | completed | Phase 3 | 10 | Northwell HealthOTHER | 1 | Apr 7, 2022 | clinicaltrials |
| NCT02313389 | Maintenance Treatment Versus Observation in Elderly Patients With PCNS Lymphoma(BLOCAGE-01) | unknown | Phase 3 | 428 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Mar 2, 2022 | clinicaltrials |
| NCT05236621 | A Study of the Efficacy and Safety of Pomalidomide Capsules Combined With Low-Dose Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma | unknown | Phase 3 | 85 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Feb 11, 2022 | clinicaltrials |
| NCT01078454 | Melphalan and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Systemic Light-Chain Amyloidosis | completed | Phase 3 | 11 | National Cancer Institute (NCI)NIH | 1 | Feb 1, 2022 | clinicaltrials |
| NCT02575144 | GEM-CLARIDEX: Ld vs BiRd(GEM-CLARIDEX) | unknown | Phase 3 | 286 | PETHEMA FoundationOTHER | 1 | Feb 1, 2022 | clinicaltrials |
| NCT05205902 | TOtal Skin Electron Beam Therapy (Low-dose) for Tumor Clone Eradication in Early-stage Mycosis Fungoides(TOTEM-01) | not yet recruiting | Phase 3 | 78 | Assistance Publique - Hôpitaux de ParisOTHER | 0 | Jan 25, 2022 | clinicaltrials |
| NCT00384111 | Phase 3 Study of Zevalin Following R-CVP in Previously Untreated Patients With Follicular Non Hodgkin's Lymphoma (NHL) | terminated | Phase 3 | 26 | Spectrum Pharmaceuticals, IncINDUSTRY | 1 | Jan 14, 2022 | clinicaltrials |
| NCT01712789 | Evaluation of Safety of Pomalidomide in Combination With Dexamethasone (Low Dose) in Patients With Refractory or Relapsed and Refractory Multiple Myeloma(STRATUS) | completed | Phase 3 | 682 | CelgeneINDUSTRY | 20 | Jan 10, 2022 | clinicaltrials |
| NCT05164770 | Study of Zanubrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma | unknown | Phase 3 | 160 | Shandong Provincial HospitalOTHER_GOV | 1 | Dec 21, 2021 | clinicaltrials |
| NCT01109004 | Stem Cell Transplant With Lenalidomide Maintenance in Patients With Multiple Myeloma (BMT CTN 0702) | completed | Phase 3 | 758 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Dec 9, 2021 | clinicaltrials |
| NCT01597778 | Double Cord Versus Haploidentical (BMT CTN 1101) | completed | Phase 3 | 368 | Medical College of WisconsinOTHER | 1 | Dec 1, 2021 | clinicaltrials |
| NCT01777152 | ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas(ECHELON-2) | completed | Phase 3 | 452 | Seagen Inc.INDUSTRY | 16 | Nov 30, 2021 | clinicaltrials |
| NCT01420679 | Pralatrexate vs Observation Following CHOP-based Chemotherapy in Undiagnosed Peripheral T-cell Lymphoma Patients | terminated | Phase 3 | 21 | Spectrum Pharmaceuticals, IncINDUSTRY | 13 | Nov 19, 2021 | clinicaltrials |
| NCT05097443 | Orelabrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma | unknown | Phase 3 | 130 | Shandong Provincial HospitalOTHER_GOV | 1 | Nov 19, 2021 | clinicaltrials |
| NCT00177047 | Autologous Transplant for Multiple Myeloma | completed | Phase 2 / Phase 3 | 363 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Nov 9, 2021 | clinicaltrials |
| NCT00000658 | A Phase III Randomized Trial of Low-Dose Versus Standard-Dose mBACOD Chemotherapy With rGM-CSF for Treatment of AIDS-Associated Non-Hodgkin's Lymphoma | completed | Phase 3 | 250 | National Institute of Allergy and Infectious Diseases (NIAID)NIH | 1 | Nov 3, 2021 | clinicaltrials |
| NCT00075829 | Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102) | completed | Phase 3 | 710 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Nov 1, 2021 | clinicaltrials |
| NCT00329030 | Rituxan/BEAM vs Bexxar/BEAM in Autologous Hematopoietic Stem Cell Transplant for Non-Hodgkin's Lymphoma (BMTCTN0401) | completed | Phase 3 | 224 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Nov 1, 2021 | clinicaltrials |
| NCT04287660 | Study of BiRd Regimen Combined With BCMA CAR T-cell Therapy in Newly Diagnosed Multiple Myeloma (MM) Patients | unknown | Phase 3 | 20 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Oct 25, 2021 | clinicaltrials |
| NCT00256776 | MMVAR - Velcade: Study of Velcade for the Treatment of Myeloma Patients After Autologous Transplantation | terminated | Phase 3 | 269 | European Society for Blood and Marrow TransplantationNETWORK | 10 | Oct 18, 2021 | clinicaltrials |
| NCT02576977 | Study of Pomalidomide and Low Dose Dexamethasone With or Without Pembrolizumab (MK-3475) in Refractory or Relapsed and Refractory Multiple Myeloma (rrMM) (MK-3475-183/KEYNOTE-183) | terminated | Phase 3 | 251 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Oct 8, 2021 | clinicaltrials |
| NCT04670029 | Impact of an APA Program on EFS in Patients With Diffuse Large-cell B Lymphoma Treated in 1st Line(PHARAOM) | recruiting | Phase 3 | 186 | WepromOTHER | 1 | Oct 8, 2021 | clinicaltrials |
| NCT01662102 | Rituximab or Zevalin - Efficacy Trial of Therapeutic Alternatives (RoZetta) | terminated | Phase 3 | 1 | Spectrum Pharmaceuticals, IncINDUSTRY | 1 | Oct 4, 2021 | clinicaltrials |
| NCT05054426 | Intermediate Dose of IV MTX as CNS Prophylaxis for High Risk DLBCL(NHL-011) | unknown | Phase 3 | 488 | Peking Union Medical College HospitalOTHER | 1 | Sep 23, 2021 | clinicaltrials |
| NCT02495922 | A Phase III Trial on the Effect of Elotuzumab in VRD Induction /Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma(GMMG-HD6) | completed | Phase 3 | 564 | University of Heidelberg Medical CenterOTHER | 1 | Sep 10, 2021 | clinicaltrials |
| NCT02631239 | MESA Versus ESA in the Treatment of Early Stage NK/T-cell Lymphoma | unknown | Phase 3 | 256 | Ruijin HospitalOTHER | 1 | Aug 25, 2021 | clinicaltrials |
| NCT05006469 | Observation of the Efficacy of BAd Regimen in the Treatment of Relapsed and Refractory Multiple Myeloma | unknown | Phase 3 | 10 | Liao AijunOTHER | 1 | Aug 16, 2021 | clinicaltrials |
| NCT01122472 | Study of Lenalidomide Maintenance Versus Placebo in Responding Elderly Patients With DLBCL and Treated With R-CHOP(REMARC) | completed | Phase 3 | 650 | The Lymphoma Academic Research OrganisationOTHER | 9 | Jul 26, 2021 | clinicaltrials |
| NCT02579863 | Study of Lenalidomide and Dexamethasone With or Without Pembrolizumab (MK-3475) in Participants With Newly Diagnosed Treatment Naive Multiple Myeloma (MK-3475-185/KEYNOTE-185) | terminated | Phase 3 | 310 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jul 20, 2021 | clinicaltrials |
| NCT04288765 | Carfilzomib, Daratumumab, Lenalidomide and Dexamethasone as First Line Treatment in Multiple Myeloma | withdrawn | Phase 3 | 0 | Grupo Cooperativo de Hemopatías MalignasOTHER | 1 | Jul 9, 2021 | clinicaltrials |
| NCT03720041 | Myeloma XIV: Frailty-adjusted Therapy in Transplant Non-Eligible Patients With Newly Diagnosed Multiple Myeloma(FiTNEss) | unknown | Phase 3 | 740 | University of LeedsOTHER | 1 | Jun 15, 2021 | clinicaltrials |
| NCT00967343 | Efficacy and Safety of a Donor Lymphocyte Preparation Depleted of Functional Host Alloreactive T-cells (ATIR) in Patients Undergoing a Peripheral Blood Stem Cell Transplant From a Related, Haploidentical Donor | terminated | Phase 2 / Phase 3 | 40 | Kiadis PharmaINDUSTRY | 7 | Jun 14, 2021 | clinicaltrials |
| NCT01419665 | GP2013 in the Treatment of Patients With Previously Untreated, Advanced Stage Follicular Lymphoma (ASSIST_FL)(ASSIST_FL) | completed | Phase 3 | 629 | SandozINDUSTRY | 26 | May 14, 2021 | clinicaltrials |
| NCT04880746 | Efficacy and Safety of Cladribine Combined With BEAC Pretreatment Regimen in the Treatment of Peripheral T-cell Lymphoma: a Multicenter Clinical Study | unknown | Phase 3 | 266 | Ruijin HospitalOTHER | 1 | May 11, 2021 | clinicaltrials |
| NCT00317096 | FCM Versus R-FCM Followed by R-Maintenance or Observation Only | unknown | Phase 3 | 319 | Ludwig-Maximilians - University of MunichOTHER | 1 | May 7, 2021 | clinicaltrials |
| NCT00773747 | Study of Vorinostat (MK-0683) or Placebo, in Combination With Bortezomib in Participants With Multiple Myeloma (MK-0683-088 AMN) | completed | Phase 3 | 637 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Apr 30, 2021 | clinicaltrials |
| NCT02112175 | Lenalidomide vs Placebo Maintenance Therapy Following Melphalan Prednisone Velcade® Induction Therapy in NDMM(ARUMM) | completed | Phase 3 | 46 | CelgeneINDUSTRY | 5 | Apr 14, 2021 | clinicaltrials |
| NCT02128061 | Efficacy of Lenalidomide in Combination With Subcutaneous Rituximab + miniCHOP in DLBCL Patients of 80 y/o or+ | completed | Phase 3 | 250 | The Lymphoma Academic Research OrganisationOTHER | 2 | Apr 13, 2021 | clinicaltrials |
| NCT02260804 | To Compare Efficacy and Safety Between CT-P10 and Rituxan in Patients With Low Tumour Burden Follicular Lymphoma | completed | Phase 3 | 258 | CelltrionINDUSTRY | 1 | Apr 8, 2021 | clinicaltrials |
Data updated 23 days agoSource updated Jul 18, 2022source: clinicaltrials